Two small keys to a locked gate: miR-221/222 unlock immune escape and chemoresistance

Immune evasion and chemoresistance are convergent barriers to durable cancer control. The microRNA cluster miR-221/222, frequently upregulated across solid tumors, has emerged as a nodal regulator of both processes. Mechanistically, miR-221/222 promote immune escape by attenuating tumor-suppressive signaling and amplifying oncogenic pathways, skewing macrophage polarization toward immunosuppressive M2 states, dampening cytotoxic T-cell activity, and conditioning pre-metastatic niches via exosomal transfer. In parallel, they reinforce therapy resistance by suppressing apoptosis, subverting cell-cycle checkpoints (e.g., p27 ^ Kip1), and activating survival cascades, notably PTEN/PI3K/AKT and SOCS3/STAT3. Although context-dependent tumor-suppressive effects have been reported, the preponderance of evidence supports a net pro-tumorigenic role. Preclinical studies indicate that targeted antagonism—using locked nucleic acids, sponges, or nanoparticle delivery—can restore chemosensitivity and potentiate immunotherapy. This review synthesizes mechanistic and translational data on miR-221/222 across malignancies, clarifies how these microRNAs integrate immune-regulatory and drug-response networks, and appraises their value as tissue and circulating biomarkers. We conclude by outlining testable therapeutic strategies, including rational combinations with checkpoint blockade and pathway inhibitors, to convert miR-221/222 from liabilities into actionable therapeutic targets.

Hali tarjima qilinmagan